Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

about

Phase 1 study of the PI3Kδ inhibitor INCB040093 ± JAK1 inhibitor itacitinib in relapsed/refractory B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q52562955

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@en

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@nl

type

Item

label

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@en

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@nl

prefLabel

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@en

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@nl

P1476

Phase 1 study of the PI3Kδ inh ...... ed/refractory B-cell lymphoma.

@en

P2093

Andres Forero-Torres

http://www.w3.org/2001/XMLSchema#string

Jennifer Pulini

http://www.w3.org/2001/XMLSchema#string

Li Zhou

http://www.w3.org/2001/XMLSchema#string

Moshe Talpaz

http://www.w3.org/2001/XMLSchema#string

Patrick Johnston

http://www.w3.org/2001/XMLSchema#string

Paul M Barr

http://www.w3.org/2001/XMLSchema#string

Peggy Scherle

http://www.w3.org/2001/XMLSchema#string

Taimur Sher

http://www.w3.org/2001/XMLSchema#string

Tycel J Phillips

http://www.w3.org/2001/XMLSchema#string

Xuejun Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Cooperative epigenetic modulation by cancer amplicon genes

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

Targeting the B-cell receptor signaling pathway in B lymphoid malignancies

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma.

Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis.

B cell development: signal transduction by antigen receptors and their surrogates.

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

B-cell receptor signaling as a driver of lymphoma development and evolution.

P304

293-306

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2017-10-812701

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

132

http://www.w3.org/2001/XMLSchema#string

P50

Catherine S.M. Diefenbach

P577

2018-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29695516

http://www.w3.org/2001/XMLSchema#string

P932

6107856

http://www.w3.org/2001/XMLSchema#string